Neoadjuvant Therapy Versus Upfront Surgery for Patients With Clinical Stage 2 or 3 Esophageal Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.

Xing GaoYu-Wen WenJoseph Jan Baptist van LanschotYin Kai Chao

Published in: Annals of surgical oncology (2022)

Because of its higher cost-effectiveness, NT is preferable to US for patients with clinical stage 3 ESCC, but US remains a viable option for stage 2 disease.

Keyphrases

minimally invasive
rectal cancer
coronary artery bypass
stem cells
squamous cell carcinoma
radiation therapy
locally advanced
mesenchymal stem cells
replacement therapy